Non-Alcoholic Steatohepatitis Biomarkers Market - Global Industry Analysis

Non-Alcoholic Steatohepatitis Biomarkers Market By Biomarker Type (Serum Biomarkers, Biomarker Panels, Fibrosis Biomarkers, and Imaging Biomarkers), By End-Users (Hospitals, Diagnostic Centers, and Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028

Published Date: 05-Aug-2022 Category: Healthcare Report Format : PDF Pages: 267 Report Code: ZMR-6113 Status : Published

The global non-alcoholic steatohepatitis biomarkers market size was worth USD 1,218.5 million in 2021 and is estimated to grow to USD 5,234.6 million by 2028, with a compound annual growth rate (CAGR) of approximately 27.5% over the forecast period.

Description

Non-Alcoholic Steatohepatitis Biomarkers Market Size And Forecast

The global non-alcoholic steatohepatitis biomarkers market size was worth USD 1,218.5 million in 2021 and is estimated to grow to USD 5,234.6 million by 2028, with a compound annual growth rate (CAGR) of approximately 27.5% over the forecast period. The report analyzes the non-alcoholic steatohepatitis biomarkers market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the non-alcoholic steatohepatitis biomarkers market.

Non-Alcoholic Steatohepatitis Biomarkers Market: Overview

Non-alcoholic fatty liver disease (NAFLD), which develops when an excessive amount of fat builds up in the liver and causes inflammation & damage that results in liver scarring, progresses to non-alcoholic steatohepatitis (NASH). A biomarker is an indication for assessing both pathogenic and normal biological processes in the body and is considered the most accurate diagnostic tool for determining the biological condition. Noninvasive technologies are referred to as biomarker tools used to diagnose NASH conditions. The reviewed market is expanding as a result of the rising prevalence of metabolic comorbidities and NASH in the general population. In addition, increased awareness of non-alcoholic fatty liver disease would open up new opportunities for the global non-alcoholic steatohepatitis biomarkers market over the anticipated period. NAFLD can be correctly diagnosed using imaging techniques such as computed tomography, magnetic resonance imaging, and ultrasound scanning. These methods, however, are ineffective for detecting liver fibrosis or NASH. In the upcoming years, it is projected that these factors will increase demand for noninvasive diagnostic tools, such as serum biomarkers, for disease detection, thereby fueling the growth of the non-alcoholic steatohepatitis biomarkers market. A surge in projects to create NASH medications creates a solid foundation for market expansion. The development of the global non-alcoholic steatohepatitis biomarkers market is being constrained by the adverse effects of NASH therapies as well as the absence of sophisticated diagnostic testing for NAFLD.

Global Non-Alcoholic Steatohepatitis Biomarkers Market

Key Insights

  • As per the analysis shared by our research analyst, the global non-alcoholic steatohepatitis biomarkers market value is to grow at a CAGR of 27.5% over the forecast period. 

  • In terms of revenue, the global non-alcoholic steatohepatitis biomarkers market size was valued at around USD 1,218.5 million in 2021 and is projected to reach USD 5,234.6 million by 2028. 
  • The market for non-alcoholic steatohepatitis biomarkers is being driven by the rising prevalence of non-alcoholic steatohepatitis (NASH), and a growing patient base suffering from diabetes and obesity.
  • As of 2021, serum biomarkers type held the majority of the market.
  • In 2021, the diagnostic center's industry dominated the market for non-alcoholic steatohepatitis biomarkers based on end-user.
  • In 2021, North America dominated the market for non-alcoholic steatohepatitis biomarkers, and it is predicted that this trend will persist over the coming years.

COVID-19 Impact:

The global non-alcoholic steatohepatitis biomarkers market growth was negatively impacted by Covid-19. Restrictions on travel and cargo movement severely disrupted the supply chain. As a result, during a few peak months, there was a market shortage of medications and medical supplies. Additionally, the temporary closure of production facilities to stop the virus's spread led to decreased output and employee layoffs. Additionally, fewer patients were attending the diagnostic centers due to travel limitations, reducing the demand for non-alcoholic steatohepatitis biomarkers. Nevertheless, the market has quickly recovered in the post-Covid period and is probably about to outpace the prior growth rate.

Non-Alcoholic Steatohepatitis Biomarkers Market: Growth Drivers

Increase in NAFLD and NASH prevalence is predicted to drive global market

Non-alcoholic liver illnesses are now occurring with greater frequency. NAFLD and other liver disorders are more common in patients with obesity and type 2 diabetes. The prevalence of liver illnesses not caused by alcohol is predicted to rise. It is projected that rising pollution levels and lifestyle changes will increase the prevalence of non-alcoholic liver disorders. Consequently, this will fuel the market for non-alcoholic steatohepatitis biomarkers.

Non-Alcoholic Steatohepatitis Biomarkers Market: Restraints

Lack of professionals and high infrastructure requirements is restraining the market growth

The lack of professionals is a major factor that is expected to limit the growth for global non-alcoholic steatohepatitis biomarkers market. The high cost of imaging testing is another issue that restrains market expansion. The analysis period's expansion of the global market may be constrained by the requirement for substantial expenditure on drug development. In addition, strict government regulations by the U.S. Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA), as well as the side effects connected with medications, are some of the factors impeding the growth of the global non-alcoholic steatohepatitis biomarkers market.

Non-Alcoholic Steatohepatitis Biomarkers Market: Segmentation

The global non-alcoholic steatohepatitis biomarkers market has been segmented into biomarker type, end-user, and region.

Based on biomarker type, the global non-alcoholic steatohepatitis biomarkers market is segmented into serum biomarkers, biomarker panels, fibrosis biomarkers, and imaging biomarkers. As of 2021, serum biomarkers held the majority of the market. These are the diagnostic techniques that are most frequently used to find NASH. Leptin, ghrelin, tumor necrosis factor-alpha, free fatty acids, apolipoprotein B, apolipoprotein A1, and adiponectin are some developing goods that can provide useful services in addition to the existing ones and are anticipated to drive the segment's growth. Serum biomarkers are also projected to dominate the segment due to their advantages, such as their capacity to distinguish between basic steatosis and NASH and provide effective results.

Based on end-user, the global non-alcoholic steatohepatitis biomarkers market is segmented into hospitals, diagnostic centers, and others. In 2021, the diagnostic center's industry dominated the market for non-alcoholic steatohepatitis biomarkers. With greater knowledge of the indications for early diagnosis and effective treatment of non-alcoholic steatohepatitis (NASH), the diagnostic centers' segment dominated the global non-alcoholic steatohepatitis biomarkers market in 2021. The diagnostic center's segment is projected to be driven by the availability of technologically sophisticated instruments like biomarkers tests in diagnostic centers combined with the presence of expertise.

Non-Alcoholic Steatohepatitis Biomarkers Market: Regional Landscape

North America dominated the non-alcoholic steatohepatitis biomarkers market in 2021

The market for non-alcoholic steatohepatitis biomarkers is expanding in North America due to causes, including supportive government policies, increased incidence of infectious disorders, cardiovascular conditions, and diabetes. Research and development funding for non-alcoholic steatohepatitis biomarkers is strong, which supports medication development efforts and fosters industry expansion. Additionally, U.S. government rules encourage research into the creation of innovative compounds, which is expected to spur industrial expansion. In this area, it is predicted that the NASH biomarkers market will grow at a profitable CAGR.

Non-Alcoholic Steatohepatitis Biomarkers Market: Competitive Landscape 

Some of the main competitors dominating the global non-alcoholic steatohepatitis biomarkers market include- Biopredictive, Quest Diagnostics, Exalenz Bioscience Ltd, GENFIT, Siemens Healthineers, ONE WAY LIVER, S.L, Prometheus Laboratories Inc, and Gilead Sciences Ltd.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Global Non-Alcoholic Steatohepatitis Biomarkers Market is segmented as follows:

By Biomarker Type

  • Serum Biomarkers
  • Biomarker Panels
  • Fibrosis Biomarkers
  • Imaging Biomarkers
  • Others

By End-User

  • Hospitals
  • Diagnostic Centers
  • Others

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market research methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market, (2022 - 2028) (USD Million)
    • 2.2 Global Non-Alcoholic Steatohepatitis Biomarkers Market : snapshot
  • Chapter 3. Global Non-Alcoholic Steatohepatitis Biomarkers Market - Industry Analysis
    • 3.1 Non-Alcoholic Steatohepatitis Biomarkers Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Increase in NAFLD and NASH prevalence is predicted to drive global market
    • 3.3 Market Restraints
      • 3.3.1. Lack of professionals and high infrastructure requirements is restraining the market growth
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market attractiveness analysis By Biomarker Type
      • 3.7.2 Market attractiveness analysis By End-User
  • Chapter 4. Global Non-Alcoholic Steatohepatitis Biomarkers Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market: company market share, 2021
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Non-Alcoholic Steatohepatitis Biomarkers Market - Biomarker Type Analysis
    • 5.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market overview: By Biomarker Type
      • 5.1.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market share, By Biomarker Type, 2021 and 2028
    • 5.2 Serum Biomarkers
      • 5.2.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market by Serum Biomarkers, 2022 - 2028 (USD Million)
    • 5.3 Biomarker Panels
      • 5.3.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market by Biomarker Panels, 2022 - 2028 (USD Million)
    • 5.4 Fibrosis Biomarkers
      • 5.4.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market by Fibrosis Biomarkers, 2022 - 2028 (USD Million)
    • 5.5 Imaging Biomarkers
      • 5.5.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market by Imaging Biomarkers, 2022 - 2028 (USD Million)
    • 5.6 Others
      • 5.6.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market by Others, 2022 - 2028 (USD Million)
  • Chapter 6. Global Non-Alcoholic Steatohepatitis Biomarkers Market - End-User Analysis
    • 6.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market overview: By End-User
      • 6.1.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market share, By End-User, 2021 and 2028
    • 6.2 Hospitals
      • 6.2.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market by Hospitals, 2022 - 2028 (USD Million)
    • 6.3 Diagnostic Centers
      • 6.3.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market by Diagnostic Centers, 2022 - 2028 (USD Million)
    • 6.4 Others
      • 6.4.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market by Others, 2022 - 2028 (USD Million)
  • Chapter 7. Non-Alcoholic Steatohepatitis Biomarkers Market - Regional Analysis
    • 7.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market Regional Overview
    • 7.2 Global Non-Alcoholic Steatohepatitis Biomarkers Market Share, by Region, 2021 & 2028 (USD Million)
    • 7.3. North America
      • 7.3.1 North America Non-Alcoholic Steatohepatitis Biomarkers Market, 2022 - 2028 (USD Million)
        • 7.3.1.1 North America Non-Alcoholic Steatohepatitis Biomarkers Market, by Country, 2022 - 2028 (USD Million)
    • 7.4 North America Non-Alcoholic Steatohepatitis Biomarkers Market, by Biomarker Type, 2022 - 2028
      • 7.4.1 North America Non-Alcoholic Steatohepatitis Biomarkers Market, by Biomarker Type, 2022 - 2028 (USD Million)
    • 7.5 North America Non-Alcoholic Steatohepatitis Biomarkers Market, by End-User, 2022 - 2028
      • 7.5.1 North America Non-Alcoholic Steatohepatitis Biomarkers Market, by End-User, 2022 - 2028 (USD Million)
    • 7.4. Europe
      • 7.4.2 Europe Non-Alcoholic Steatohepatitis Biomarkers Market, 2022 - 2028 (USD Million)
        • 7.4.2.1 Europe Non-Alcoholic Steatohepatitis Biomarkers Market, by Country, 2022 - 2028 (USD Million)
    • 7.4 Europe Non-Alcoholic Steatohepatitis Biomarkers Market, by Biomarker Type, 2022 - 2028
      • 7.4.1 Europe Non-Alcoholic Steatohepatitis Biomarkers Market, by Biomarker Type, 2022 - 2028 (USD Million)
    • 7.5 Europe Non-Alcoholic Steatohepatitis Biomarkers Market, by End-User, 2022 - 2028
      • 7.5.1 Europe Non-Alcoholic Steatohepatitis Biomarkers Market, by End-User, 2022 - 2028 (USD Million)
    • 7.5. Asia Pacific
      • 7.5.3 Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, 2022 - 2028 (USD Million)
        • 7.5.3.1 Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, by Country, 2022 - 2028 (USD Million)
    • 7.4 Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, by Biomarker Type, 2022 - 2028
      • 7.4.1 Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, by Biomarker Type, 2022 - 2028 (USD Million)
    • 7.5 Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, by End-User, 2022 - 2028
      • 7.5.1 Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, by End-User, 2022 - 2028 (USD Million)
    • 7.6. Latin America
      • 7.6.4 Latin America Non-Alcoholic Steatohepatitis Biomarkers Market, 2022 - 2028 (USD Million)
        • 7.6.4.1 Latin America Non-Alcoholic Steatohepatitis Biomarkers Market, by Country, 2022 - 2028 (USD Million)
    • 7.4 Latin America Non-Alcoholic Steatohepatitis Biomarkers Market, by Biomarker Type, 2022 - 2028
      • 7.4.1 Latin America Non-Alcoholic Steatohepatitis Biomarkers Market, by Biomarker Type, 2022 - 2028 (USD Million)
    • 7.5 Latin America Non-Alcoholic Steatohepatitis Biomarkers Market, by End-User, 2022 - 2028
      • 7.5.1 Latin America Non-Alcoholic Steatohepatitis Biomarkers Market, by End-User, 2022 - 2028 (USD Million)
    • 7.7. The Middle-East and Africa
      • 7.7.5 The Middle-East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market, 2022 - 2028 (USD Million)
        • 7.7.5.1 The Middle-East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market, by Country, 2022 - 2028 (USD Million)
    • 7.4 The Middle-East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market, by Biomarker Type, 2022 - 2028
      • 7.4.1 The Middle-East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market, by Biomarker Type, 2022 - 2028 (USD Million)
    • 7.5 The Middle-East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market, by End-User, 2022 - 2028
      • 7.5.1 The Middle-East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market, by End-User, 2022 - 2028 (USD Million)
  • Chapter 8. Company Profiles
    • 8.1 Biopredictive
      • 8.1.1 Overview
      • 8.1.2 Financials
      • 8.1.3 Product Portfolio
      • 8.1.4 Business Strategy
      • 8.1.5 Recent Developments
    • 8.2 Quest Diagnostics
      • 8.2.1 Overview
      • 8.2.2 Financials
      • 8.2.3 Product Portfolio
      • 8.2.4 Business Strategy
      • 8.2.5 Recent Developments
    • 8.3 Exalenz Bioscience Ltd
      • 8.3.1 Overview
      • 8.3.2 Financials
      • 8.3.3 Product Portfolio
      • 8.3.4 Business Strategy
      • 8.3.5 Recent Developments
    • 8.4 GENFIT
      • 8.4.1 Overview
      • 8.4.2 Financials
      • 8.4.3 Product Portfolio
      • 8.4.4 Business Strategy
      • 8.4.5 Recent Developments
    • 8.5 Siemens Healthineers
      • 8.5.1 Overview
      • 8.5.2 Financials
      • 8.5.3 Product Portfolio
      • 8.5.4 Business Strategy
      • 8.5.5 Recent Developments
    • 8.6 ONE WAY LIVER
      • 8.6.1 Overview
      • 8.6.2 Financials
      • 8.6.3 Product Portfolio
      • 8.6.4 Business Strategy
      • 8.6.5 Recent Developments
    • 8.7 S.L
      • 8.7.1 Overview
      • 8.7.2 Financials
      • 8.7.3 Product Portfolio
      • 8.7.4 Business Strategy
      • 8.7.5 Recent Developments
    • 8.8 Prometheus Laboratories Inc
      • 8.8.1 Overview
      • 8.8.2 Financials
      • 8.8.3 Product Portfolio
      • 8.8.4 Business Strategy
      • 8.8.5 Recent Developments
    • 8.9 Gilead Sciences Ltd.
      • 8.9.1 Overview
      • 8.9.2 Financials
      • 8.9.3 Product Portfolio
      • 8.9.4 Business Strategy
      • 8.9.5 Recent Developments

Table Of Figures

  • 1. Market research Type
  • 2. Market research methodology
  • 3. Global Non-Alcoholic Steatohepatitis Biomarkers Market, 2022 - 2028 (USD Million)
  • 4. Porter’s Five Forces Analysis
  • 5. Global Non-Alcoholic Steatohepatitis Biomarkers Market attractiveness, By Biomarker Type
  • 6. Global Non-Alcoholic Steatohepatitis Biomarkers Market attractiveness, By End-User
  • 7. Global Non-Alcoholic Steatohepatitis Biomarkers Market share by Biomarker Type, 2022 and 2028 (USD Million)
  • 8. Global Non-Alcoholic Steatohepatitis Biomarkers Market by Serum Biomarkers, 2022 - 2028 (USD Million)
  • 9. Global Non-Alcoholic Steatohepatitis Biomarkers Market by Biomarker Panels, 2022 - 2028 (USD Million)
  • 10. Global Non-Alcoholic Steatohepatitis Biomarkers Market by Fibrosis Biomarkers, 2022 - 2028 (USD Million)
  • 11. Global Non-Alcoholic Steatohepatitis Biomarkers Market by Imaging Biomarkers, 2022 - 2028 (USD Million)
  • 12. Global Non-Alcoholic Steatohepatitis Biomarkers Market by Others, 2022 - 2028 (USD Million)
  • 13. Global Non-Alcoholic Steatohepatitis Biomarkers Market share by End-User, 2022 and 2028 (USD Million)
  • 14. Global Non-Alcoholic Steatohepatitis Biomarkers Market by Hospitals, 2022 - 2028 (USD Million)
  • 15. Global Non-Alcoholic Steatohepatitis Biomarkers Market by Diagnostic Centers, 2022 - 2028 (USD Million)
  • 16. Global Non-Alcoholic Steatohepatitis Biomarkers Market by Others, 2022 - 2028 (USD Million)
  • 17. Global Non-Alcoholic Steatohepatitis Biomarkers Market share, by Region, 2022 and 2028
  • 18. North America Non-Alcoholic Steatohepatitis Biomarkers Market, 2022 - 2028 (USD Million)
  • 19. Europe Non-Alcoholic Steatohepatitis Biomarkers Market, 2022 - 2028 (USD Million)
  • 20. Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, 2022 - 2028 (USD Million)
  • 21. Latin America Non-Alcoholic Steatohepatitis Biomarkers Market, 2022 - 2028 (USD Million)
  • 22. The Middle-East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market, 2022 - 2028 (USD Million)

Table Of Tables

  • 1. Global Non-Alcoholic Steatohepatitis Biomarkers Market: Snapshot
  • 2. Drivers of the Non-Alcoholic Steatohepatitis Biomarkers Market: impact analysis
  • 3. North America Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 4. North America Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 5. U.S. Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 6. U.S. Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 7. Canada Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 8. Canada Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 9. Europe Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 10. Europe Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 11. Germany Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 12. Germany Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 13. France Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 14. France Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 15. U.K. Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 16. U.K. Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 17. Italy Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 18. Italy Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 19. Spain Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 20. Spain Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 21. Rest of Europe Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 22. Rest of Europe Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 23. Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 24. Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 25. China Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 26. China Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 27. Japan Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 28. Japan Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 29. India Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 30. India Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 31. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 32. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 33. South-East Asia Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 34. South-East Asia Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 35. Rest of Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 36. Rest of Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 37. Latin America Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 38. Latin America Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 39. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 40. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 41. Mexico Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 42. Mexico Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 43. Rest of Latin America Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 44. Rest of Latin America Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 45. The Middle-East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 46. The Middle-East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 47. GCC Countries Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 48. GCC Countries Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 49. South Africa Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 50. South Africa Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)
  • 51. Rest of Middle-East Africa Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By Biomarker Type, 2022 - 2028 (USD Million)
  • 52. Rest of Middle-East Africa Non-Alcoholic Steatohepatitis Biomarkers Market revenue, By End-User, 2022 - 2028 (USD Million)

Methodology

Choose License Type

FrequentlyAsked Questions

In the next years, demand for noninvasive diagnostic techniques is likely to increase due to the rising prevalence of chronic liver disorders. Over the projection period, the demand for noninvasive diagnostic tools is likely to increase along with patient awareness levels, which is expected to support the development of non-alcoholic steatohepatitis biomarkers.

According to the report, the global non-alcoholic steatohepatitis biomarkers market size was worth USD 1,218.5 million in 2021 and is estimated to grow to USD 5,234.6 million by 2028, with a compound annual growth rate (CAGR) of approximately 27.5% over the forecast period.

The market for non-alcoholic steatohepatitis biomarkers is expanding in North America due to a number of causes, including supportive government policies, the increased incidence of infectious disorders, cardiovascular conditions, and diabetes.

Some of the main competitors dominating the global non-alcoholic steatohepatitis biomarkers market include- Biopredictive, Quest Diagnostics, Exalenz Bioscience Ltd, GENFIT, Siemens Healthineers, ONE WAY LIVER, S.L, Prometheus Laboratories Inc, and Gilead Sciences Ltd.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed